Tuberculosis

March 10, 2020

Repurposing the anti-asthmatic drug Montelukast into an anti-tuberculosis drug: Montelukast (trade name: Singulair) deacetylates RelA/p65, inhibits inflammatory gene expression downstream of RelA/p65, inhibits TB pathogenesis, increases the efficacy of anti-TB drug, and promotes M. tuberculosis clearance via upregulation of its target gene, 10/March/2020, 8.01 am

Repurposing the anti-asthmatic drug Montelukast into an anti-tuberculosis drug: Montelukast (trade name: Singulair) deacetylates RelA/p65, inhibits inflammatory gene expression downstream of RelA/p65, inhibits TB pathogenesis, increases the efficacy of anti-TB drug, and promotes M. tuberculosis clearance via upregulation of its target gene, 10/March/2020, 8.01 am https://genomediscovery.org/wp-content/uploads/2020/03/Montelukast-protects-against-drug-resistant-Tuberculosis-through-deacetylation-of-p65.RelA_.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2020/03/Montelukast-protects-against-drug-resistant-Tuberculosis-through-deacetylation-of-p65.RelA_.jpg March 10, 2020 March 10, 2020

Introduction: What they say: A study from the Singapore Immunology Network, Agency for Science, Technology and Research, Singapore; and Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore shows…

April 8, 2019

Probiotic-based therapy for tuberculosis: Probiotic Lactobacillus fermentum CQPC08 (LFCQPC08) deacetylates RelA/p65, inhibits inflammatory gene expression downstream of RelA/p65, inhibits TB pathogenesis, increases the efficacy of anti-TB drug, and promotes M. tuberculosis clearance via upregulation of its target gene, 8/April/2019, 11.53 pm

Probiotic-based therapy for tuberculosis: Probiotic Lactobacillus fermentum CQPC08 (LFCQPC08) deacetylates RelA/p65, inhibits inflammatory gene expression downstream of RelA/p65, inhibits TB pathogenesis, increases the efficacy of anti-TB drug, and promotes M. tuberculosis clearance via upregulation of its target gene, 8/April/2019, 11.53 pm https://genomediscovery.org/wp-content/uploads/2019/04/Probiotic-Lactobacillus-fermentum-CQPC08-LFCQPC08-protects-against-drug-resistant-Tuberculosis-through-deacetylation-of-p65.RelA_.jpg2_.jpg 1280 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2019/04/Probiotic-Lactobacillus-fermentum-CQPC08-LFCQPC08-protects-against-drug-resistant-Tuberculosis-through-deacetylation-of-p65.RelA_.jpg2_.jpg April 8, 2019 April 8, 2019

April 8, 2019

Repurposing the anti-diabetic drug Metformin into an anti-tuberculosis drug: Metformin (trade name: Glucophage, Glumetza, Glucophage XR, Fortamet), the widely used drug in the treatment of TIIDM, deacetylates RelA/p65, inhibits inflammatory gene expression downstream of RelA/p65, inhibits TB pathogenesis, increases the efficacy of anti-TB drug, and promotes M. tuberculosis clearance via upregulation of its target gene, 8/April/2019, 9.50 pm

Repurposing the anti-diabetic drug Metformin into an anti-tuberculosis drug: Metformin (trade name: Glucophage, Glumetza, Glucophage XR, Fortamet), the widely used drug in the treatment of TIIDM, deacetylates RelA/p65, inhibits inflammatory gene expression downstream of RelA/p65, inhibits TB pathogenesis, increases the efficacy of anti-TB drug, and promotes M. tuberculosis clearance via upregulation of its target gene, 8/April/2019, 9.50 pm https://genomediscovery.org/wp-content/uploads/2019/04/Metformin-protects-against-drugresistant-tuberculosis-through-deacetylation-of-p65.RelA_.jpg 1280 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2019/04/Metformin-protects-against-drugresistant-tuberculosis-through-deacetylation-of-p65.RelA_.jpg April 8, 2019 April 8, 2019

March 28, 2019

Molecular therapy for tuberculosis: AS-2, a derivative of 8-Hydroxyquinoline (8HQ), deacetylates RelA/p65, inhibits inflammatory gene expression downstream of RelA/p65, inhibits TB pathogenesis, increases the efficacy of anti-TB drug, and promotes M. tuberculosis clearance, via upregulation of its target gene, 28/March/2019, 6.51 am

Molecular therapy for tuberculosis: AS-2, a derivative of 8-Hydroxyquinoline (8HQ), deacetylates RelA/p65, inhibits inflammatory gene expression downstream of RelA/p65, inhibits TB pathogenesis, increases the efficacy of anti-TB drug, and promotes M. tuberculosis clearance, via upregulation of its target gene, 28/March/2019, 6.51 am https://genomediscovery.org/wp-content/uploads/2019/03/AS-2-Hydroxyquinoline-derivative-protects-against-drug-resistant-tuberculosis-through-deacetylation-of-p65.RelA_.jpg 1280 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2019/03/AS-2-Hydroxyquinoline-derivative-protects-against-drug-resistant-tuberculosis-through-deacetylation-of-p65.RelA_.jpg March 28, 2019 March 28, 2019

March 28, 2019

Molecular therapy for tuberculosis (TB): Clioquinol[iodochlorhydroxyquin] (Trade name:Cortin), an antifungal and antiprotozoal drug that inhibits certain enzymes related to DNA replication, deacetylates RelA/p65, inhibits inflammatory gene expression downstream of RelA/p65, inhibits TB pathogenesis, increases the efficacy of anti-TB drug, and promotes M. tuberculosis clearance via upregulation of its target gene, 28/March/2019, 5.47 am

Molecular therapy for tuberculosis (TB): Clioquinol[iodochlorhydroxyquin] (Trade name:Cortin), an antifungal and antiprotozoal drug that inhibits certain enzymes related to DNA replication, deacetylates RelA/p65, inhibits inflammatory gene expression downstream of RelA/p65, inhibits TB pathogenesis, increases the efficacy of anti-TB drug, and promotes M. tuberculosis clearance via upregulation of its target gene, 28/March/2019, 5.47 am https://genomediscovery.org/wp-content/uploads/2019/03/Clioquinol-CQ-5-chloro-7-iodo-8-hydroxyquinoline-protects-against-drug-resistant-tuberculosis-through-deacetylation-of-p65.RelA_.jpg 1280 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2019/03/Clioquinol-CQ-5-chloro-7-iodo-8-hydroxyquinoline-protects-against-drug-resistant-tuberculosis-through-deacetylation-of-p65.RelA_.jpg March 28, 2019 March 28, 2019

February 14, 2019

Molecular therapy for tuberculosis: Ezetimibe (brand name:Zetia, Ezetrol), a drug used to lower blood cholesterol, deacetylates RelA/p65, inhibits inflammatory gene expression downstream of RelA/p65, inhibits TB pathogenesis, increases the efficacy of anti-TB drug, and promotes M. tuberculosis clearance via upregulation of its target gene, 14/February/2019, 11.23 pm

Molecular therapy for tuberculosis: Ezetimibe (brand name:Zetia, Ezetrol), a drug used to lower blood cholesterol, deacetylates RelA/p65, inhibits inflammatory gene expression downstream of RelA/p65, inhibits TB pathogenesis, increases the efficacy of anti-TB drug, and promotes M. tuberculosis clearance via upregulation of its target gene, 14/February/2019, 11.23 pm https://genomediscovery.org/wp-content/uploads/2019/02/Ezetimibe-attenuates-drug-resistant-TB.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2019/02/Ezetimibe-attenuates-drug-resistant-TB.jpg February 14, 2019 February 14, 2019

Popular Post